AlanSandlerMD

Hematology • South San Francisco, CA

Professor of Medicine, Oregon Health & Sci University

Join to view full profile

Dr. Sandler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sandler's full profile

Already have an account?

Office
1 DNA Drive
South San Francisco, CA 94080
Phone+1 650-477-6605

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Yale-New Haven Medical CenterResidency, Internal Medicine, 1987 - 1989
Rush Medical College of Rush University Medical CenterClass of 1987

Certifications & Licensure

OR State Medical License 2009 - 2019

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

Clinical Trials

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Start of enrollment: 2010 May 01
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

843 citations
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre
The New England Journal of Medicine. 2020-09-30
2048 citations
Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial
Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste
Lancet. 2016-04-30
3332 citations
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello
Lancet. 2017-01-21

Journal Articles

Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences